The drug company, which uses artificial intelligence to discover and advance repurposed drugs, is harnessing the technology to find a treatment for Crohn’s.
After 30 years’ experience, including stints advising top pharma firms, the expert has joined a firm offering tech aimed at elevating patient ID and enrollment.
The two companies have joined forces to collaborate on the commercial launch of Gimoti, a nasal spray for patients suffering from diabetic gastroparesis.
